Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Hemicrania Continua
NCT04303845Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in hemicrania continua (HC), sponsored by Mayo Clinic. Started Aug 2021; status: terminated.
02
Drugs
erenumab
03
Conditions
hemicrania continua (HC)
Beyond the preview
Go deeper on NCT04303845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303845.